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Introduction {#sec007}
============

*Histoplasma* spp. are environmental fungi capable of causing a wide range of human illnesses following inhalation. Most infections are asymptomatic or go unrecognized, and a smaller proportion of people develop acute or chronic pulmonary infection, disseminated disease, or other infectious or inflammatory sequelae.\[[@pone.0230305.ref001]\] Presumed ocular histoplasmosis syndrome (POHS) is a vision-threatening condition believed to be a long-term complication of *Histoplasma* infection; however, the link between *Histoplasma* and POHS remains somewhat controversial. Evidence supporting this relationship includes experimental infections of non-human primates, positive associations between POHS and histoplasmin skin test positivity, and the presence of POHS cases in areas where *Histoplasma* is known to be endemic.\[[@pone.0230305.ref002]--[@pone.0230305.ref006]\] In contrast, POHS has also been described in Europe where *Histoplasma* is not believed to be common,\[[@pone.0230305.ref007]--[@pone.0230305.ref009]\] although the fungus is more widespread than is currently appreciated,\[[@pone.0230305.ref010]\] and it is also possible that a different organism could be causing a similar syndrome in those areas. *Histoplasma* has never been cultured from a POHS-affected eye, although POHS is thought to represent a complication of infection rather than active infection. Despite the uncertainty surrounding its etiology and pathogenesis, POHS is a well-recognized entity characterized by "punched-out" round chorioretinal scars, peripapillary atrophy, the absence of vitritis, and risk of choroidal neovascularization (CNV). For some persons, these lesions do not impair vision and only require routine monitoring, whereas CNV can lead to vision loss, requiring treatment with intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections or photodynamic therapy (PDT).

POHS has received little attention from a public health perspective in recent years. Given the large population residing in highly histoplasmosis-endemic areas in the United States, POHS could potentially affect hundreds of thousands of people. Furthermore, little is known about non-geographical risk factors, vision morbidity, and medical costs associated with developing CNV secondary to POHS. Here, we describe features of POHS patients with and without CNV in a large database of patients with commercial insurance, including testing, treatment, and associated direct medical costs. We hope that an updated epidemiologic description of POHS will help to increase awareness about histoplasmosis and POHS, with the ultimate goal of identifying and implementing strategies for early diagnosis and prevention.

Methods {#sec008}
=======

We used the 2014--2016 IBM^®^ MarketScan^®^ Commercial Database and the Medicare Supplemental Database, which contain individual-level health insurance claims and enrollment data for people with employer-sponsored insurance and their dependents throughout the United States. The MarketScan Research Databases are fully de-identified, so this analysis was not subject to review by the Centers for Disease Control and Prevention (CDC) institutional review board.

We used International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis codes 115.02, 115.12, and 115.92 to identify patients with at least one outpatient claim for histoplasmosis retinitis in 2014. The index date was the date this code was first used in 2014, and we limited the cohort to patients who were continuously enrolled for 2 years after the index date. Here, we use the term POHS to refer to histoplasmosis retinitis codes, because it is more widely used in the literature. To identify features related to POHS diagnosis, treatment, and outcomes in the 2-year study window, we used ICD-9-CM, ICD-10-CM, and Current Procedural Terminology (CPT) codes ([S1 Table](#pone.0230305.s001){ref-type="supplementary-material"}). We calculated average patient and insurer costs associated with specific treatments for POHS. We used the Medical Care Consumer Price Index from the Bureau of Labor Statistics, US Department of Labor, to adjust costs to 2017 US Dollars.

We performed descriptive analyses and examined differences between patients with and without CNV using χ2 or Fisher exact tests for categorical variables and t-tests or Wilcoxon rank-sum tests for continuous variables. To contextualize the prevalence of POHS in the MarketScan population, we also determined the number of patients in 2014 with ICD-9-CM codes on outpatient claims for any type of histoplasmosis (115.x) as well as certain other causes of eye infection: herpetic eye disease (054.40, 054.42, 054.43, 054.44, and 054.49), toxoplasmosis retinitis (130.2), and syphilis retinitis (090.0, 090.3, 090.40, 090.49, 090.5, 091.5x, 094.3, 094.83, 094.85, 094.89, and 094.9).

Results {#sec009}
=======

Of more than 50 million total MarketScan enrollees in 2014, 6,678 had an ICD-9-CM code for histoplasmosis retinitis on an outpatient claim (POHS patients), compared with 15,122 for herpetic eye disease, 1,499 for syphilis retinitis, and 1,326 for toxoplasmosis retinitis. Among patients with any histoplasmosis ICD-9-CM code (115.x), 69% had histoplasmosis retinitis codes, and 9% had a code for "unspecified histoplasmosis" assigned by an eye care provider. Of the 6,678 POHS patients, 2,718 were enrolled for 2 years after the index date ([Fig 1](#pone.0230305.g001){ref-type="fig"}). Of those, 698 (25%) had at least one diagnosis code for CNV, and 2,029 (75%) did not.

![Enrollment and treatment, patients with presumed ocular histoplasmosis syndrome, 2014.](pone.0230305.g001){#pone.0230305.g001}

CNV patients were significantly younger (mean 53.4 vs. 58.2 years, p\<0.0001) and more likely to be male (39% vs. 35%, p\<0.0482) than those without CNV ([Table 1](#pone.0230305.t001){ref-type="table"}). Half (50%) of POHS patients lived in the South census region, and 41% lived in the Midwest ([Fig 2](#pone.0230305.g002){ref-type="fig"}). POHS rates (including patients not enrolled for the entire study window) among MarketScan enrollees were highest in the lower Midwest and South Central regions, with lower rates in surrounding states and very low rates in much of New England and the West. In contrast, rates of herpetic eye disease, syphilis retinitis, and toxoplasmosis retinitis clustered less by region ([S1](#pone.0230305.s002){ref-type="supplementary-material"}--[S3](#pone.0230305.s004){ref-type="supplementary-material"} Figs).

![Rates of presumed ocular histoplasmosis syndrome per 100,000 MarketScan enrollees, 2014.\
\*To avoid unreliable estimates, rates not calculated for states with \<5 cases. Reporting MarketScan data from South Carolina is not permitted.](pone.0230305.g002){#pone.0230305.g002}

10.1371/journal.pone.0230305.t001

###### Demographic features and specific diagnoses or procedures among patients with presumed ocular histoplasmosis syndrome, 2014.

![](pone.0230305.t001){#pone.0230305.t001g}

  Demographics at index date                                     ALL PATIENTS   NO CNV   CNV          p-value                         
  -------------------------------------------------------------- -------------- -------- ------------ --------- ------------ -------- ----------
  Age in years, median, mean (range)                             58.0, 57.0     1--95    59.0, 58.2   1--95     55.0, 53.4   15--95   \<0.0001
  Age group in years                                                                                                                  \<0.0001
   0--17                                                         24             1%       21           1%        3            0%       
   18--34                                                        162            6%       100          5%        62           9%       
   35--44                                                        319            12%      194          10%       125          18%      
   45--54                                                        552            20%      402          20%       150          22%      
   55--64                                                        921            34%      701          35%       220          32%      
   65 and older                                                  740            27%      611          30%       129          19%      
  Sex                                                                                                                                 0.0482
   Male                                                          988            36%      716          35%       272          39%      
   Female                                                        1730           64%      1313         65%       417          61%      
  Census division of primary beneficiary's residence                                                                                  0.4741
   New England                                                   18             1%       14           1%        4            1%       
   Mid-Atlantic                                                  118            4%       83           4%        34           5%       
   East North Central                                            887            33%      667          33%       220          32%      
   West North Central                                            217            8%       154          8%        63           9%       
   South Atlantic                                                355            13%      257          13%       99           14%      
   East South Central                                            760            28%      576          28%       183          27%      
   West South Central                                            283            10%      222          11%       61           9%       
   Mountain                                                      28             1%       19           1%        10           1%       
   Pacific                                                       51             2%       36           2%        15           2%       
   Unknown                                                       1              0%       1            0%        0            0%       
  **Other diagnoses or procedures in the 2-year study window**                                                                        
  Disseminated histoplasmosis                                    17             1%       13           1%        4            1%       1.0000
  Unspecified or other forms of histoplasmosis                   919            34%      521          26%       398          58%      \<0.0001
  Pulmonary histoplasmosis                                       12             0%       6            0%        6            1%       0.0871
  Histoplasmosis antibody or antigen test                        28             1%       14           1%        14           2%       0.0026
  Fungal culture or smear                                        127            5%       98           5%        29           4%       0.5046
  Chorioretinitis                                                74             3%       49           2%        25           4%       0.0908
  Vitreous disorders                                             720            26%      495          24%       225          33%      \<0.0001
  Diabetic retinopathy                                           86             3%       66           3%        20           3%       0.6501
  Diabetic macular edema                                         24             1%       18           1%        6            1%       0.9685
  Macular degeneration (AMD)                                     652            24%      410          20%       242          35%      \<0.0001
  History of or current tobacco use                              312            11%      232          11%       80           12%      0.8999

Macular degeneration was more frequently coded for CNV patients than for non-CNV patients (35% vs. 20%,), as were vitreous disorders (33% vs. 24%) (p\<0.0001 for both). Eleven percent (n = 312) had diagnosis codes for a history of or current tobacco use, but there was no difference between CNV and non-CNV patients.

Most patients (86%, n = 2,326) visited an eye care provider on the index date, and nearly half (49%, n = 1,320) had a CPT code for a routine eye examination on the index date (52% of non-CNV patients vs. 38% of CNV patients, p\<0.0001) ([Table 2](#pone.0230305.t002){ref-type="table"}). CNV patients had significantly more visits (mean 8.8, range 0--46) to an eye care provider during the study window than non-CNV patients (mean 3.2, range 0--42) (P\<0.0001). Nearly all (92%) CNV patients had CPT codes for optical coherence tomography (OCT), vs. approximately one-third (35%) of non-CNV patients (p\<0.0001), and 79% of CNV patients underwent OCT ≥3 times during the 2-year follow up period. CNV patients were also more likely to undergo fluorescein angiography (38%) than were non-CNV patients (8%) (p\<0.0001).

10.1371/journal.pone.0230305.t002

###### Diagnosis, treatment, and outcomes among patients with presumed ocular histoplasmosis syndrome, 2014.

![](pone.0230305.t002){#pone.0230305.t002g}

                                                                  ALL PATIENTS   NO CNV    CNV          p-value                          
  --------------------------------------------------------------- -------------- --------- ------------ --------- ------------ --------- ----------
  Visited an eye care provider on the index date                  2326           86%       1716         85%       610          89%       0.0106
  Routine eye examination during study window                     1871           69%       1386         68%       485          70%       0.3079
  Routine eye examination on the index date                       1320           49%       1061         52%       259          38%       \<0.0001
  Mean, median number of visits to an eye care provider (range)   4.7, 3.0       (0--46)   3.2, 2.0     (0--42)   8.8, 7.0     (0--46)   \<0.0001
   0 visits                                                       304            11%       250          12%       54           8%        
   1 visit                                                        449            17%       422          21%       27           4%        
   2 visits                                                       559            21%       508          25%       51           7%        
   3 or more visits                                               1406           52%       849          42%       557          81%       
  Intravitreal injection                                          565            21%       113          6%        452          66%       \<0.0001
  Subtenon injection                                              10             0%        3            0%        7            1%        0.0038
  Steroid injection                                               325            12%       248          12%       77           11%       0.4642
  Oral steroids (n = 2576)                                        845            33%       635          33%       210          32%       0.5740
  Any anti-VEGF injection                                         391            14%       84           4%        307          45%       \<0.0001
   Mean, median number of injections (range)                      7.1, 5.0       (1--44)   (8.0, 5.0)   1--44     (6.9, 4.0)   1--43     0.2996
  Aflibercept                                                     69             3%        27           1%        42           6%        \<0.0001
  Ranibizumab                                                     30             1%        20           1%        40           6%        \<0.0001
  Bevacizumab                                                     305            11%       48           2%        257          37%       \<0.0001
  Fluorescein angiography                                         420            15%       159          8%        261          38%       \<0.0001
   Once                                                           114            27%       41           26%       73           28%       
   Twice                                                          182            43%       88           55%       94           36%       
   Three or more times                                            124            30%       30           19%       94           36%       
  Photodynamic therapy                                            37             1%        4            0%        33           5%        \<0.0001
   Once                                                           5              14%       2            25%       3            9%        
   Twice                                                          21             57%       2            25%       19           58%       
   Three or more times                                            11             30%       0            0%        11           33%       
  Optical coherence tomography                                    1339           49%       707          35%       632          92%       \<0.0001
   Once                                                           354            26%       295          42%       59           9%        
   Twice                                                          230            17%       159          22%       71           11%       
   Three or more times                                            755            56%       253          36%       502          79%       
  Fundus photography                                              1114           41%       791          39%       323          47%       0.0003
   Once                                                           610            55%       448          57%       162          50%       
   Twice                                                          320            29%       239          30%       81           25%       
   Three or more times                                            184            17%       104          13%       80           25%       
  Vision loss                                                     57             2%        35           2%        22           3%        0.0201

Two-thirds (66%) of CNV patients received an intravitreal injection with any agent (e.g., anti-VEGF agents, corticosteroids) compared with 6% of non-CNV patients (p\<0.0001). Forty-five percent (n = 307) of CNV patients received at least one anti-VEGF injection, with a mean of 6.9 injections (range 1--43) during the 2-year study window; 37% received bevacizumab, 6% received aflibercept, and 6% received ranibizumab. Five percent of CNV patients received photodynamic therapy vs. \<1% of non-CNV patients. CNV and non-CNV patients were equally likely to receive corticosteroid injections (11% vs. 12%) or oral corticosteroids (32% vs. 33%). Diagnosis codes for vision loss were infrequent but more common for patients with CNV than for those without (3% vs. 2%, p = 0.02).

The mean total yearly patient out-of-pocket cost for POHS-related visits was \$64.32 for non-CNV patients (\$187.04 to the insurer) and \$248.19 for CNV patients (\$1,003.64 to the insurer) (p\<0.0001) ([Table 3](#pone.0230305.t003){ref-type="table"}). The mean costs of an anti-VEGF injection were \$50.98 to patients and \$884.67 to the insurer, with mean total cost being highest for aflibercept (\$2,256.17) and lowest for bevacizumab (\$122.07). Mean total cost of photodynamic therapy was also substantial (\$891.14).

10.1371/journal.pone.0230305.t003

###### Mean costs of visits and treatments related to presumed ocular histoplasmosis syndrome, 2014.

![](pone.0230305.t003){#pone.0230305.t003g}

  Mean costs                                    ALL PATIENTS   NO CNV    CNV       p-value
  --------------------------------------------- -------------- --------- --------- ----------
  Cost of POHS visit to patient                 80.58          68.63     91.91     \<0.0001
  Cost of POHS visit to insurer                 288.26         200.33    371.63    \<0.0001
  Cost of intravitreal injection to patient     39.14          22.99     42.86     \<0.0001
  Cost of intravitreal injection to insurer     169.05         143.82    174.87    \<0.0001
  Cost of anti-VEGF injection to patient        50.98          66.62     46.02     0.0094
  Cost of anti-VEGF injection to insurer        884.67         1295.48   754.47    \<0.0001
  Cost of aflibercept to patient                97.04          80.77     106.11    0.1331
  Cost of aflibercept to insurer                2159.13        2124.92   2178.20   0.5125
  Cost of ranibizumab to patient                130.52         162.04    115.25    0.1028
  Cost of ranibizumab to insurer                2036.77        1955.84   2075.96   0.1059
  Cost of bevacizumab to patient                12.46          6.95      13.63     \<0.0001
  Cost of bevacizumab to insurer                109.61         347.45    59.16     \<0.0001
  Cost of photodynamic therapy to patient       185.23         529.80    164.76    0.3645
  Cost of photodynamic therapy to insurer       705.91         711.36    705.59    0.9873
  Total yearly cost of POHS visits to patient   113.32         64.32     248.19    \<0.0001
  Total yearly cost of POHS visits to insurer   404.64         187.04    1003.64   \<0.0001

To assess the potential contribution of age-related macular degeneration (AMD) to treatments and outcomes among POHS patients, we examined the POHS cohort after excluding the 652 patients who had AMD codes. Compared with the full cohort, the remaining 2,066 POHS patients without AMD were younger (median 56 vs. 58 years) and less frequently had CNV codes (22% vs. 26%), any intravitreal injection (14% vs. 21%), and any anti-VEGF injection (9% vs. 14%). The mean total yearly patient out-of-pocket cost for POHS-related visits was \$97.68 for those without AMD vs. \$113.32 for the full cohort, and total yearly cost to insurer was \$259.08 vs. \$404.64.

Discussion {#sec010}
==========

We describe a large cohort of patients with diagnosis codes for POHS in the United States using medical claims data from a commercially-insured population. Our results show that the prevalence of POHS is approximately 13 cases per 100,000 MarketScan enrollees, with a geographic pattern consistent with the traditionally described distribution of *Histoplasma*, concentrated around the Ohio and Mississippi River Valleys. Remarkably, it accounted for over two-thirds of overall histoplasmosis claims of any type, including the pulmonary form thought to be much more common. In accordance with the known predisposition for POHS to cause asymptomatic scarring in some people and devastating vision loss in others, in this cohort, CNV was associated with certain demographic features, greater healthcare usage, and higher costs, which has implications from clinical, health economics, and public health perspectives.

POHS is often described in scientific literature as a "leading cause of vision loss" among young adults in the United States, though the precise origin of this statement is unclear. Despite the fact that MarketScan databases are not directly representative of the national population and that we were unable to calculate prevalence rates in the continuously-enrolled POHS patient group, POHS diagnoses were not uncommon based solely on the number of cases, particularly compared with other infectious causes of retinitis such as syphilis and toxoplasmosis.

Much of the information about the estimated prevalence of POHS and its complications is half a century old. Studies performed in the 1960s and 70s identified rates of POHS in the general community ranging from 1.6% in Ohio \[[@pone.0230305.ref002]\] to 2.7% in Maryland, with a slightly higher prevalence (4.4%) among persons with positive histoplasmin skin tests.\[[@pone.0230305.ref011]\] Large-scale histoplasmin skin tests surveys conducted in the 1940s and 50s identified nine states (Alabama, Arkansas, Illinois, Indiana, Iowa, Kentucky, Missouri, Ohio, Tennessee) with large areas of positivity rates \>70%.\[[@pone.0230305.ref012]\] Applying this proportion to the nearly 60 million people currently living in those areas, we estimate that 42 million people would have positive histoplasmin skin tests (although the test is now unavailable), and of those, 672,000 would have ocular findings consistent with POHS in those 9 states alone, using the most conservative estimate of POHS prevalence of 1.6%. In our analysis, up to a quarter of patients with POHS diagnosis codes also had CNV coded and therefore likely have some degree of vision loss. It is unclear to what extent these patients represent the broader population with POHS, but regardless they suggest that POHS-induced vision defects may be relatively common. Although vision loss is difficult to ascertain with administrative data and appears to be substantially under-coded, most patients with CNV likely experience some degree of vision impairment. Additional research to understand the current prevalence of POHS and associated vision loss would help to understand its importance in the context of other major causes of vision loss and impairment.

A fundamental question about POHS is whether it is truly caused by *Histoplasma*. In this analysis, the geographic distribution of POHS patients was remarkably similar to that of positive histoplasmin skin test results,\[[@pone.0230305.ref012]\] which could support the conclusion that *Histoplasma* infection is a causative component of POHS. This pattern could be influenced by greater provider awareness of POHS in known endemic areas, but it is unlikely to be completely explained by this phenomenon alone. In general, histoplasmosis is an under-recognized infection in the United States,\[[@pone.0230305.ref013]\] and information about its long-term sequelae, including POHS, is limited. We hope that that future experimental and epidemiologic studies can further clarify the relationship between *Histoplasma* and POHS. One study provided promising evidence by detecting *H*. *capsulatum* DNA in a patient's chronic choroidal lesions.\[[@pone.0230305.ref014]\]

In this cohort, one-quarter of patients had CNV diagnosis codes, which is higher than the estimate that fewer than 5% of people with POHS develop CNV.\[[@pone.0230305.ref015]\] The high proportion with CNV seen here could represent selection bias towards patients who are more likely to be symptomatic and therefore seek care. An alternative explanation for the high prevalence of CNV could be related to misclassification with AMD, which also appeared to be common. Although it seems unlikely that patients would have both AMD and POHS, clinical phenotypic similarities including retinal pigment epithelium atrophy and pigment change may be observed in both conditions, leading to use of both diagnostic codes. The young age of patients with POHS and CNV suggests POHS as the predisposing disease entity versus AMD. Additionally, although CNV and intravitreal injections were less common among POHS patients without AMD codes than those with AMD codes, nearly a quarter of non-AMD POHS patients had CNV and one in seven received intravitreal injections, suggesting that POHS is independently associated with CNV, apart from AMD.

Another notable demographic finding is the higher proportion of POHS in females, whereas previous studies have shown that POHS appears to affect males and females similarly \[[@pone.0230305.ref011]\] or have a slight predominance in males, similar to histoplasmosis in general.\[[@pone.0230305.ref006], [@pone.0230305.ref013]\] These differences could be related to the convenience sample nature of MarketScan data or to differences in care-seeking behavior by sex. In contrast to prior reports, we did not find an association between smoking and CNV.\[[@pone.0230305.ref016]\] This could be due to under-coding of smoking status in administrative data or to our use of POHS patients without CNV as the comparison group, if smoking increases the risk for POHS itself. This explanation seems plausible given the higher rate of previous or current tobacco use in POHS patients (11%) compared with the general MarketScan population (7%).

The pattern of retinal imaging for initial diagnosis and follow-up monitoring was notable. In this cohort, patients with CNV were more likely to undergo OCT and FA testing than non-CNV patients, consistent with the need for routine monitoring in active CNV, including follow-up of treatment with anti-VEGF injection and PDT. Together, this monitoring and treatment was responsible for the substantially greater cost to the patient and insurer of CNV.

Our finding that over half of non-CNV POHS patients had a routine eye examination on the index date supports the notion that many POHS cases are discovered incidentally and might only require routine observation to monitor for the development of CNV. Requiring a specific period of time without the diagnosis of interest (i.e., POHS) before the index date is a common method in claims-based research to attempt to identify incident cases. However, establishing such a time window is difficult for long-term conditions such as POHS; therefore, our cohort includes both incident and prevalent cases. Among patients with POHS diagnosis codes in 2014, 28%, 50%, and 55% of patients also had POHS diagnosis codes in the 1 year, 2, years, and 3 years before the index date, respectively, confirming disease monitoring over several years. Consequently, CNV is likely over-represented in our cohort, in addition to previously mentioned reasons related to potential misclassification of macular degeneration and selection bias.

Formal treatment guidelines for POHS do not currently exist. Antifungal therapy is not indicated because POHS is not believed to represent an active infectious process.\[[@pone.0230305.ref017]\] A common approach to managing POHS patients without CNV includes patient education about the risk of developing CNV and the importance of self-monitoring for vision changes. Treatment of CNV is often successful with administration of anti-VEGF agents.\[[@pone.0230305.ref018], [@pone.0230305.ref019]\] Our findings are consistent with these management patterns, with most of the anti-VEGF agent use occurring in the CNV group. PDT and corticosteroid use were also observed although with lower frequency compared with anti-VEGF therapy. Moreover, our estimates of OCT frequency are consistent with OCT-guided personalized treatment for CNV described in the literature and likely reflect current clinical practice. However, the treatment algorithms (i.e., treat-and-extend vs. treatment pro re nata \[PRN\]) could not be ascertained from this dataset.

Total yearly costs associated with POHS were substantial, exceeding \$500 per patient, though we were not able to approximate total costs nationwide. The overall economic burden of major eye disorders in the US is estimated to be more than \$35 billion among adults \>40 years alone, only 46% of which is attributable to direct medical costs.\[[@pone.0230305.ref020]\] Our cost estimates do not capture direct nonmedical costs or indirect costs, which are likely to be substantial for POHS patients with CNV-associated vision impairment, as has been previously shown for patients with AMD.\[[@pone.0230305.ref021]\] Specifically, we found that the costs associated with anti-VEGF treatments were high, with some patients receiving many injections during the study window. A recent European study concluded that bevacizumab was more cost-effective than ranibizumab or aflibercept for treatment of AMD.\[[@pone.0230305.ref022]\] Although we were not able to evaluate cost-effectiveness, bevacizumab was used more commonly than other anti-VEGF agents in our study, likely due to its lower cost and previously described efficacy.\[[@pone.0230305.ref023]\]

In addition to the limited information available about the overall magnitude of POHS as a cause of vision loss in the United States, few published data exist regarding its personal burden on patients, though a small qualitative study suggests that POHS patients can experience substantial emotional distress and impaired productivity due to vision loss and treatment-related side effects.\[[@pone.0230305.ref024]\] Greater awareness about POHS among the medical community and increased collaborations across specialties and disciplines (i.e., ophthalmologists, general practitioners, infectious disease specialists, and public health professionals) could be helpful to better characterize the syndrome and its effects on patients.

Strengths of this study include the large sample size and the ability to examine diagnosis and procedure codes over a 2-year period. The limitations of using administrative data for epidemiologic studies are well-recognized and have been previously reviewed specifically in the context of ophthalmology research.\[[@pone.0230305.ref025]\] Misclassification due to unintentional miscoding or coding practices that influence reimbursement is a particularly important consideration in analyses of billing data \[[@pone.0230305.ref026]\]. For example, patients may be assigned AMD diagnosis codes to obtain reimbursement for anti-VEGF injections. Evaluating clinical features such as disease severity is another common challenge with claims-based data, although the presence of a CNV code among patients with histoplasmosis retinitis codes appeared to identify more patients with more severe cases in this analysis. Unfortunately, single codes to identify "histoplasmosis retinitis" are no longer available in the ICD-10-CM coding system; instead, POHS diagnoses are coded using B39 for histoplasmosis and H32 for "chorioretinal disorders in diseases classified elsewhere." From a public health perspective, this change could potentially make tracking POHS trends more challenging. Lastly, because these MarketScan data only represent people with private insurance, the findings might not be generalizable to uninsured people or those with government insurance plans without supplemental insurance coverage.

Our study did not address the role of early detection and treatment in preventing further complications in POHS-associated CNV, but this remains an important goal. Future research is warranted to better understand *Histoplasma* as a possible cause of POHS and risk factors for developing POHS and associated vision loss.
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###### Rates of herpetic eye disease per 100,000 MarketScan enrollees, 2014.

\*To avoid unreliable estimates, rates not calculated for states with \<5 cases. Reporting MarketScan data from South Carolina is not permitted.
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###### Rates of syphilis retinitis per 100,000 MarketScan enrollees, 2014.

\*To avoid unreliable estimates, rates not calculated for states with \<5 cases. Reporting MarketScan data from South Carolina is not permitted.

(TIF)
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###### Rates of toxoplasmosis retinitis per 100,000 MarketScan enrollees, 2014.

\*To avoid unreliable estimates, rates not calculated for states with \<5 cases. Reporting MarketScan data from South Carolina is not permitted.

(TIF)
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